Endometriosis Drug Pipeline — PatSnap Eureka
Endometriosis Drug Pipeline: GnRH Antagonists, Progesterone Modulators & Anti-Inflammatory Targets
Endometriosis affects an estimated 10–20% of women of reproductive age. The therapeutic landscape is shifting from GnRH agonist paradigms toward oral non-peptide antagonists, next-generation progesterone modulators, and novel anti-inflammatory mechanisms including CGRP/RAMP1 blockade and IL-11 pathway inhibition.
Key Molecular Targets in the Pipeline
Ten distinct targets identified across patent filings in this dataset
An Estrogen-Responsive, Progesterone-Resistant Inflammatory Disease
Endometriosis is consistently framed across retrieved patent filings as an estrogen-responsive and progesterone-unresponsive condition — a characterisation explicitly stated in a Texas A&M University System filing, which establishes progesterone resistance as a defining molecular feature. This mechanistic framing drives the diversity of therapeutic approaches now entering the pipeline.
The disease is characterised by functional endometrial tissue growing outside the uterine cavity, causing dysmenorrhea, menorrhagia, pelvic pain, and reduced fertility. Multiple Jenapharm GmbH & Co. KG and Bayer Schering Pharma filings describe it as a proliferative, hormone-dependent gynecological disorder. According to WHO, endometriosis affects roughly 10% of women of reproductive age globally — though patent-based estimates in this dataset cite 10–20%.
The PatSnap life sciences intelligence platform enables researchers and IP teams to map the full molecular target landscape for conditions like endometriosis, identifying white spaces and freedom-to-operate risks across modalities. Understanding the disease's dual hormonal and inflammatory biology is essential for interpreting the divergent IP strategies documented here.
A 2022 clinical guideline paper from the University of Tokyo Department of Obstetrics and Gynecology documents the real-world transition from GnRH agonist-dominated therapy to dienogest and GnRH antagonist regimens in Japan — providing direct clinical evidence context for the patent signals described in this report.
Six Drug Classes Reshaping the Endometriosis Pipeline
From commercially advanced GnRH antagonists to preclinical anti-inflammatory biologics, the pipeline spans hormonal suppression, receptor modulation, and novel immune targets.
Oral Non-Peptide GnRH Antagonists
ObsEva S.A. holds the most concentrated single-assignee portfolio in this dataset, claiming linzagolix (thieno[3,4-d]pyrimidine derivative) across WO, US, AU, SG, JP, and CA. AbbVie Inc. (with Neurocrine Biosciences) claims elagolix sodium formulation IP in IL and SG. Key differentiators include oral bioavailability, AMH/E2 biomarker-guided dosing, and fertility recovery windows via treatment interruption — addressing bone mineral density liabilities of predecessor GnRH agonists.
Linzagolix · Elagolix · Multi-jurisdictionalProgesterone Receptor Modulators (Mesoprogestins & SPRMs)
Jenapharm GmbH & Co. KG, Schering Aktiengesellschaft, and Bayer Schering Pharma filings span 2001–2010 across at least 9 jurisdictions. Mesoprogestins (J867, J912, J900, J914, J1042) stabilise PR at an intermediate agonist/antagonist state not reachable by pure progestins or antiprogestins. Bayer Pharma separately claims vilaprisan (SPRM) for endometriosis, fibroids, and meningioma. The J-series IP estate is largely inactive — a potential freedom-to-operate opportunity for next-generation programs.
Mesoprogestins · Vilaprisan · CDB-4124Gestagen-Class Progestogens (Dienogest)
Bayer Schering Parma claims dienogest at doses up to twice the ovulation-inhibiting dose without bone density loss. Zimmermann, Holger holds a US patent for continuous dienogest or cyproterone acetate for at least 169 days or 25 weeks with demonstrated pain reduction. The 2022 University of Tokyo clinical guideline documents the introduction of dienogest as marking a paradigm shift from GnRH agonist-dominated therapy in Japan — the only direct clinical signal in this dataset. Miscon Trading S.A. additionally claims intralesional progestogen delivery via transvaginal, endoscopic, or laparoscopic routes.
Dienogest · Cyproterone Acetate · Intralesional deliveryProstaglandin EP2/EP4 Receptor Antagonists
Texas A&M University System and inventor Arosh, Joe A. claim selective inhibition of PGE2 receptors EP2 and EP4 via novel cell signaling mechanisms — purportedly without compromising reproductive function, a key claimed advantage over hormonal approaches. Pfizer Limited filed pyrrolidine and azetidine-based EP2 antagonists (SG, JP, 2011) for endometriosis and uterine fibroids, extending this target into small-molecule drug design. All filings in this class are preclinical with no clinical signals in the retrieved dataset.
EP2 · EP4 · Fertility-preserving claimPatent Activity & Development Stage Across Therapeutic Classes
Derived from patent and literature signals in this dataset. Development stage is inferred from filing breadth, vintage, and clinical context — not from regulatory submissions.
Key Assignee Jurisdictional Breadth
ObsEva leads with 6 jurisdictions for linzagolix; Bayer entities span the broadest organisational footprint (2001–2022).
Pipeline Development Stage Distribution
GnRH antagonists are the only advanced/commercial-stage class; the majority of novel targets remain preclinical.
Patent Filing Timeline by Modality
Mesoprogestin filings begin 2001; CGRP/RAMP1 is the most recently dated filing (2024), signalling an emerging frontier.
Mechanism Category: Hormonal vs. Non-Hormonal Targets
Non-hormonal, mechanism-specific approaches represent the highest-risk/highest-reward frontier — avoiding reproductive axis suppression.
Key Patent-Driving Organisations in the Endometriosis Pipeline
Patent activity is heavily dominant in this dataset. Academic literature is represented by one clinical guideline and one diagnostic biomarker study.
| Assignee | Primary Target / Modality | Key Compounds / Agents | Jurisdictions | Filing Span | Stage (Inferred) |
|---|---|---|---|---|---|
| ObsEva S.A. | GnRH Receptor Antagonist | Linzagolix (thieno[3,4-d]pyrimidine) | WO, US, AU, SG, JP, CA | 2020–2022 | Advanced/Commercial |
| Bayer (all entities) | PR Modulators, SPRMs, Anti-PRLR, IL-11 | J-series, Vilaprisan, 005-C04/006-H08 antibodies | AU, EP, NO, NZ, SK, BG, TR, RS, WO | 2001–2022 | Clinical / Preclinical |
| AbbVie Inc. (+ Neurocrine Biosciences) | GnRH Receptor Antagonist | Elagolix sodium | IL, SG | 2020 | Advanced/Commercial |
| Miscon Trading S.A. | Progestogens (Intralesional delivery) | Progesterone, Gestodene, Norgestimate | EP, AU, CA, PL, ES, PH | Multiple (inactive) | Inactive/Legacy |
| Texas A&M / Arosh, Joe A. | PGE2 EP2/EP4 Receptor Antagonists | 6-isopropoxy-9-oxoxanthene-2-carboxylic acid (EP2); morpholine cyclopentyl heptenoic acid (EP4) | US, WO | 2010 | Preclinical |
| Pfizer Limited | EP2 Antagonists, NGF Antagonists | Pyrrolidines, Azetidines | SG, JP, WO, CA | 2010–2011 | Preclinical/Legacy |
| Ferring B.V. | Anti-Angiogenic (Dopamine D2 agonist) | Quinagolide | WO, US, PL, EP | Multiple | Preclinical |
| Children's Medical Center Corporation | CGRP/RAMP1 Signaling | Rimegepant, Fremanezumab, Galcanezumab | WO | 2024 | Preclinical (IND-enabling) |
| Yeda Research & Development Co. Ltd | MMP-7 Selective Antibody | Anti-MMP-7 monoclonal antibody | IL (pending) | 2023 | Preclinical |
Track assignee activity and portfolio changes in real time
Set up patent monitoring alerts for every organisation in this landscape using PatSnap Eureka.
Key Strategic Implications for Drug Developers & IP Teams
Derived from patent filing patterns, assignee activity, and translational signals identified in this dataset.
GnRH Antagonist IP Is Layered and Contested
ObsEva S.A. holds multi-jurisdictional linzagolix filings through 2022, while AbbVie/Neurocrine claims elagolix formulation IP. Companies entering this space face layered composition-of-matter and formulation patent barriers. Freedom-to-operate due diligence is required, particularly for oral non-peptide thieno[3,4-d]pyrimidine chemotypes, as noted in PatSnap's IP analytics platform.
Mesoprogestin IP Estate Is Largely Inactive — Freedom to Operate Opportunity
The J-series mesoprogestin IP estate (Jenapharm/Schering/Bayer lineage) is largely inactive, presenting potential freedom-to-operate for next-generation PRM drug programs. The pharmacological distinction between mesoprogestins, full PR antagonists (CDB-4124), and gestagens (dienogest) is IP-distinct — each represents a separate design space. Explore white spaces via PatSnap's customer success case studies.
Combination Approaches & Precision Medicine Signals
Retrieved results signal several combination and emerging directions within the endometriosis pipeline. ObsEva's filings across multiple jurisdictions describe dosing schedules that allow temporary cessation of GnRH antagonist to restore hormonal cycling — effectively functioning as an intermittent add-back strategy to reduce bone density effects while maintaining endometriosis suppression.
Endorecherche, Inc. (HK, 2013) claims co-administration of a SERM with LHRH agonists or antagonists, with optional sex steroid precursors (DHEA, DHEA-S), suggesting a multi-target hormonal modulation strategy. Syng Pharmaceuticals explicitly claims that SNCG inhibitors potentiate the efficacy of other hormonal agents — framing this as a combination-eligible mechanism.
A particularly significant emerging direction is CGRP repurposing from migraine. The Children's Medical Center Corporation's 2024 WO filing signals potential repurposing of clinically available CGRP pathway agents (gepants, anti-CGRP antibodies) for endometriosis-associated pain and lesion biology — a direction that could accelerate clinical translation given existing FDA-approved agents in this class. Researchers can track repurposing signals systematically using PatSnap's open API and data integration tools.
Biomarker-stratified therapy selection is an emerging IP battleground. Cedars-Sinai Medical Center (WO/AU, 2024–2026) and Feinstein Institutes for Medical Research (WO/CA/US, 2023–2025) are filing methods for treating endometriosis patients stratified by immune cell compositions (NK cells, T-cells, B-cells) in endometrial tissue — signalling a potential companion diagnostic plus therapeutic co-development opportunity. The PatSnap life sciences intelligence suite supports this kind of multi-modal IP landscape analysis.
Endometriosis Drug Pipeline — Key Questions Answered
The endometriosis therapeutic landscape includes oral non-peptide GnRH antagonists (linzagolix, elagolix), progesterone receptor modulators (mesoprogestins, SPRMs such as vilaprisan, full antagonists such as CDB-4124), gestagen-class progestogens (dienogest, cyproterone acetate), prostaglandin EP2/EP4 receptor antagonists, and novel anti-inflammatory approaches targeting MMP-7, CGRP/RAMP1, and IL-11/IL-11RA.
GnRH antagonists suppress ovarian estrogen production via the hypothalamic-pituitary-gonadal axis. Oral non-peptide GnRH antagonists such as linzagolix (ObsEva) and elagolix (AbbVie/Neurocrine) address the bone mineral density loss and injection-route liabilities of predecessor GnRH agonists, offering oral bioavailability and dosing flexibility. ObsEva's filings additionally claim AMH/E2 biomarker-guided dosing regimens for individualised therapy.
Mesoprogestins are compounds with mixed progesterone receptor (PR) agonist/antagonist activity that stabilise PR function at an intermediate state not reachable by pure progestins or antiprogestins. Named compounds include J867, J912, J900, J914, and J1042, with daily doses of 0.5–100 mg. The mesoprogestin IP estate (J-series, Jenapharm/Schering/Bayer lineage) is largely inactive, presenting potential freedom-to-operate for next-generation PRM drug programs.
Non-hormonal targets in the endometriosis pipeline include MMP-7 (selective anti-MMP-7 monoclonal antibody shown to reduce lesion weight in vivo; antibodies against MMP-9 and TACE did not — establishing MMP-7 specificity), CGRP/RAMP1 signaling (using agents such as rimegepant, fremanezumab, and galcanezumab repurposed from migraine), IL-11/IL-11RA (Bayer's function-blocking antibodies showing p < 0.0001 uterine weight reduction in mouse models), and PGE2 EP2/EP4 receptor antagonists (claimed to spare ovarian function and fertility).
In this dataset, ObsEva S.A. holds the most concentrated single-assignee GnRH antagonist portfolio with filings across WO, US, AU, SG, JP, and CA (2020–2022). Bayer entities (Jenapharm, Schering, Bayer Schering Pharma, Bayer Pharma, Bayer Aktiengesellschaft, Bayer Intellectual Property GmbH) have the broadest organisational footprint, covering mesoprogestins, SPRMs, anti-PRLR antibodies, and IL-11 pathway inhibitors across patents spanning 2001 to 2022. AbbVie Inc. (with Neurocrine Biosciences) holds elagolix formulation IP in IL and SG jurisdictions.
The Children's Medical Center Corporation (WO, 2024) filed the most recently dated therapeutic patent in this dataset, claiming methods for treating endometriosis pain and reducing lesion size via agents inhibiting CGRP/RAMP1 signaling. Preclinical mouse data using von Frey testing, abdominal contortion frequency, and lesion size measurements across rimegepant, fremanezumab, and galcanezumab represent IND-enabling preclinical evidence and a translational repurposing signal from migraine therapeutics.
Still have questions? Let PatSnap Eureka search the patent literature for you.
Ask PatSnap Eureka About Endometriosis DrugsAccelerate Your Endometriosis Drug Discovery & IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to map molecular targets, identify freedom-to-operate, and track emerging pipeline signals across life sciences.
References
- GnRH Antagonists for the Treatment of Estrogen-Dependent Disorders — ObsEva S.A., 2021, WO [Patent]
- Compositions and Methods for the Treatment of Estrogen-Dependent Disorders — ObsEva S.A., 2021, WO [Patent]
- Gonadotropin-Releasing Hormone Antagonist Dosing Regimens for the Treatment of Endometriosis — ObsEva S.A., 2020, AU [Patent]
- Compositions and Methods for the Treatment of Adenomyosis and Rectovaginal Endometriosis — ObsEva S.A., 2020, CA [Patent]
- Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome and Adenomyosis — AbbVie Inc., 2020, IL [Patent]
- Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis — AbbVie Inc., 2020, SG [Patent]
- Mesoprogestins for the Treatment and Prevention of Benign Hormone Dependent Gynecological Disorders — Jenapharm GmbH & Co. KG, 2002, EP [Patent]
- Mesoprogestins (Progesterone Receptor Modulators) for the Treatment and Prevention of Benign Hormone Dependent Gynecological Disorders — Jenapharm GmbH & Co. KG, 2010, BG [Patent]
- Mesoprogestins (Progesterone Receptor Modulators) for the Treatment and Prevention of Benign Hormone Dependent Gynecological Disorders — Schering Aktiengesellschaft, 2001, AU [Patent]
- (11β,17β)-17-Hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the Treatment of Diseases — Bayer Pharma Aktiengesellschaft, 2019, TR [Patent]
- Progesterone Antagonists such as CDB-4124 in the Treatment of Endometriosis, Uterine Fibroids, Dysmenorrhea, Breast Cancer — Allergan Pharmaceuticals International Limited, 2012, IL [Patent]
- Pharmaceutical Preparation to Reduce Endometriosis — Bayer Schering Parma Aktiengesellschaft, 2009, CR [Patent]
- Pharmaceutical Preparation Containing a Gestagen, and Kit and Method for Treating Endometriosis — Zimmermann, Holger, 2008, US [Patent]
- Clinical Practice Guidelines for Endometriosis in Japan (The 3rd Edition) — Department of Obstetrics and Gynecology, The University of Tokyo, 2022 [Paper]
- Inhibition of Prostaglandin E2 Receptors for the Treatment of Endometriosis — Arosh, Joe A. (Texas A&M University System), 2010, WO [Patent]
- Pyrrolidines — Pfizer Limited, 2011, SG [Patent]
- Azetidine as an EP2 Antagonist — Pfizer Limited, 2011, JP [Patent]
- Compositions for Use in the Treatment of Endometriosis — Yeda Research and Development Company Ltd, 2023, IL [Patent]
- CGRP/RAMP1 Blockade to Treat Endometriosis-Associated Pain and Reduce Endometriosis Lesions — The Children's Medical Center Corporation, 2024, WO [Patent]
- Inhibitors of IL-11 or IL-11RA for Use in the Treatment of Abnormal Uterine Bleeding — Bayer Aktiengesellschaft, 2022, WO [Patent]
- Treatment of Endometriosis — Pfizer Limited, 2010, WO [Patent]
- Neutralizing Prolactin Receptor Antibodies and Their Therapeutic Use — Bayer Intellectual Property GmbH, 2017, RS [Patent]
- WHO — Endometriosis Fact Sheet [World Health Organization]
- NIH — Endometriosis Research and Clinical Information [National Institutes of Health]
- FDA — Drug Approvals and Databases: Endometriosis Indications [U.S. Food and Drug Administration]
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within the retrieved patent and literature dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.